Phase III trial for KLU156 (ganaplacide/lumefantrine, or GanLum), meets primary endpoint of non-inferiority to standard of care Coartem® (artemether-lumefantrine) Demonstrates PCR-corrected cure rate ...
Phase III trial for KLU156 (ganaplacide/lumefantrine, or GanLum), meets primary endpoint of non-inferiority to standard of care Coartem® (artemether-lumefantrine) Demonstrates PCR-corrected cure rate ...
Enanta Pharmaceuticals, Inc.'s strong pipeline, positive RSV drug data, and solid cash position drive growth. Click for my ...
For patients across all indications treated within the RP2D range early, promising progression-free survival (PFS) and ...
Continued execution on collaborations and exploratory investigator-initiated studies with institutional partners Secured net proceeds of approximately $3.9 million from October 2025 offering ...
Finance Income, net, was $0.1 million for the three months ended September 30, 2025, compared to $1.5 million in the same ...
Topline data from Phase 3 (IOB-013) clinical trial in advanced melanoma presented at ESMO; data highlights improvements in PFS achieved in overall population and across virtually all subgroups, althou ...
Gold faces volatility from tightening liquidity, rising yields, and weak freight data but strong support, seasonal trends, ...
Q3 2025 Earnings Call Transcript November 13, 2025Protalix BioTherapeutics, Inc. misses on earnings expectations.
The S&P 1500 Health Care Index advanced 4.0% in the third quarter, underperforming the S&P 500, which gained 8.1%. Read more ...
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) Q3 2025 Earnings Call Transcript November 12, 2025 Acurx Pharmaceuticals, Inc.
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback